HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Utility of a Second 99mTc-MIBI Scintigraphy Before Reoperation for Patients With Persistent Sporadic Primary Hyperparathyroidism: Results of a Retrospective Multicenter Study.

AbstractBACKGROUND:
Persistent primary hyperparathyroidism (PHPT) occurs in 2.5% to 15% of cases after parathyroidectomy. Few studies have evaluated the best pre-reoperative imaging approaches for persistent sporadic PHPT. This retrospective multicenter study aimed to evaluate the benefit of a second pre-reoperative 99mTc-methoxy-isobutyl-isonitrile (MIBI) scintigraphy for patients with persistent PHPT who had a 99mTc-MIBI before their initial surgery.
METHODS:
The study enrolled 50 patients with persistent sporadic PHPT who had reoperation between 2006 and 2016 in three French University Hospitals (Angers, Nantes, and La Pitié Salpêtrière-Paris). Preoperative 99mTc-MIBI scan was performed before each operation.
RESULTS:
After the reoperation, 42 patients (84%) were cured. By the second 99mTc-MIBI, 31 patients (62%) had a removed gland identified. A new pathologic gland was identified by a second 99mTc-MIBI in 25 patients (50%), and this imaging permitted correction of an initial surgical error in six patients (12%). A second 99mTc-MIBI showed a sensitivity of 63%, a specificity of 89%, a positive predictive value (PPV) of 78%, and a negative predictive value (NPV) of 80%. A concordant second 99mTc-MIBI and ultrasonography (17 patients) showed a sensitivity of 70%, a specificity of 81%, a PPV of 70%, and an NPV of 81%.
CONCLUSIONS:
Performing a second 99mTc-MIBI scan permitted 62% of the persistent PHPT patients to be cured, allowing identification of new pathologic glands in 50% of the cases and correction of an initial surgical error in 12% of the cases, with high specificity and PPV. These results reinforce the fact that a second 99mTc-MIBI scan should be performed at first intention before reoperation of patients with persistent PHPT, regardless of the result from the initial 99mTc-MIBI scan.
AuthorsSamuel Frey, Clément Couëtte, Christophe Trésallet, Antoine Hamy, Cécile Caillard, Claire Blanchard, Fabrice Menegaux, Nathalie Chereau, Matthieu Wargny, Charlotte Lussey-Lepoutre, Delphine Drui, Catherine Ansquer, Eric Mirallié
JournalAnnals of surgical oncology (Ann Surg Oncol) Vol. 27 Issue 10 Pg. 3831-3839 (Oct 2020) ISSN: 1534-4681 [Electronic] United States
PMID32246313 (Publication Type: Journal Article, Multicenter Study)
Chemical References
  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi
Topics
  • Humans
  • Hyperparathyroidism, Primary (diagnostic imaging, surgery)
  • Parathyroid Glands
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Reoperation
  • Retrospective Studies
  • Technetium Tc 99m Sestamibi

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: